Becton Dickinson and Company (BDX)vsFemasys Inc (FEMY)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
FEMY
Femasys Inc
$0.51
-0.06%
HEALTHCARE · Cap: $33.17M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 1063397% more annual revenue ($21.92B vs $2.06M). BDX leads profitability with a 8.0% profit margin vs 0.0%. BDX earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
FEMY
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Intrinsic value data unavailable for FEMY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Revenue surging 31.4% year-over-year
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -3.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : FEMY
The strongest argument for FEMY centers on Revenue Growth. Revenue growth of 31.4% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : FEMY
The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BDX profiles as a value stock while FEMY is a hypergrowth play — different risk/reward profiles.
BDX carries more volatility with a beta of 0.31 — expect wider price swings.
FEMY is growing revenue faster at 31.4% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 23/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Femasys Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Femasys Inc. is an innovative medical technology firm at the forefront of transforming women's healthcare through its proprietary solutions aimed at diagnosing and treating gynecological conditions. The company is particularly recognized for its flagship products that offer non-surgical alternatives for common issues such as uterine fibroids and contraception, positioning it as a leader in the evolving landscape of women's health. As demand for minimally invasive procedures grows, Femasys is strategically positioned to capitalize on this trend, enhancing patient outcomes while optimizing healthcare delivery. With a commitment to addressing significant unmet needs in women's health, Femasys aims to revolutionize the standards of care in this vital sector.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?